Metastatic Breast Cancer

Personalized Therapy Shows Promise in Metastatic Breast Cancer

Personalized Therapy Shows Promise in Metastatic Breast Cancer

A personalized therapy can mediate complete durable cancer regression, according to study results.

cfDNA Profiling Prognostic for Survival in Metastatic Triple-Negative Breast Cancer

cfDNA Profiling Prognostic for Survival in Metastatic Triple-Negative Breast Cancer

By

Despite other clinicopathologic factors, patients with a tumor fraction of 10% or greater were more than twice as likely to pass away as those with a fraction of less than 10%.

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

By

Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

By

A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

By

A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.

Avelumab Demonstrated Clinical Activity in Subset of Patients With Metastatic Breast Cancer

Avelumab Demonstrated Clinical Activity in Subset of Patients With Metastatic Breast Cancer

By

Avelumab has an acceptable safety profile in patients with metastatic breast cancer and demonstrated signs of greater clinical activity in specific subsets of patients.

ASCO: Palbociclib increases survival for HR+ metastatic breast cancer

ASCO: Palbociclib increases survival for HR+ metastatic breast cancer

Adding palbociclib to standard hormone therapy may be more beneficial than hormone therapy alone for HR+/HER2− breast cancer, according to a new study.

Ginger as a treatment for breast cancer

Ginger as a treatment for breast cancer

Research published in the Journal of Biomedicine and Biotechnology suggests that ginger may be a promising breast cancer treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs